Clinical parameters | OS | PFS | ||||
---|---|---|---|---|---|---|
No a | HR (95% CI) b | p | No a | HR (95% CI) b | p | |
Age | Â | Â | 0.414 | Â | Â | 0.762 |
 ≤ 60 years | 49 | 1 |  | 43 | 1 |  |
 > 60 years | 70 | 1.24 (0.74–2.06) |  | 62 | 1.08 (0.67–1.72) |  |
Residual tumor mass |  |  | < 0.001 |  |  | < 0.001 |
 0 mm | 60 | 1 |  | 58 | 1 |  |
 > 0 mm | 57 | 3.80 (2.17–6.65) |  | 47 | 2.41 (1.53–3.90) |  |
Ascites fluid volume | Â | Â | 0.005 | Â | Â | 0.019 |
 ≤ 500 ml | 66 | 1 |  | 61 | 1 |  |
 > 500 ml | 46 | 2.10 (1.25–3.54) |  | 38 | 1.79 (1.10–2.90) |  |
FIGO stage | Â | Â | 0.215 | Â | Â | 0.360 |
 IIIA + IIIB | 13 | 1 |  | 12 | 1 |  |
 IIIC + IV | 106 | 1.90 (0.69–5.24) |  | 93 | 1.44 (0.63–3.14) |  |
KLK5 mRNA c | Â | Â | 0.269 | Â | Â | 0.047 |
 low | 73 | 1 |  | 62 | 1 |  |
 high | 45 | 1.33 (0.80–2.20) |  | 42 | 1.60 (1.01–2.55) |  |